{"id":70600,"date":"2026-07-24T21:04:23","date_gmt":"2026-07-24T13:04:23","guid":{"rendered":"https:\/\/flcube.com\/?p=70600"},"modified":"2026-07-24T21:04:25","modified_gmt":"2026-07-24T13:04:25","slug":"lillys-retatrutide-delivers-up-to-22-6-weight-loss-in-phase-3-trials-establishing-triple-agonist-leadership-in-obesity-market","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70600","title":{"rendered":"Lilly&#8217;s Retatrutide Delivers Up to 22.6% Weight Loss in Phase 3 Trials, Establishing Triple Agonist Leadership in Obesity Market"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Eli Lilly and Company<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/LLY:NYSE\">NYSE: LLY<\/a>) announced on <strong>July 23, 2026<\/strong> positive topline results from <strong>TRIUMPH-2 and TRIUMPH-3<\/strong>, two pivotal Phase 3 trials evaluating <strong>retatrutide<\/strong>, an investigational <strong>first-in-class triple hormone receptor agonist<\/strong> targeting GIP, GLP-1, and glucagon receptors. The studies demonstrated <strong>substantial weight loss<\/strong> in adults with obesity and its complications, including type 2 diabetes and established cardiovascular disease, positioning retatrutide as a potential best-in-class therapy in the rapidly expanding obesity treatment market.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-results-summary\" class=\"wp-block-heading\">Clinical Trial Results Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study<\/th><th>Population<\/th><th>Doses<\/th><th>Weight Loss (Average)<\/th><th>A1C Reduction<\/th><\/tr><\/thead><tbody><tr><td><strong>TRIUMPH-2<\/strong><\/td><td>Adults with obesity + type 2 diabetes<\/td><td>4 mg<\/td><td>29.8 lbs (12.7%)<\/td><td>Up to 1.6%<\/td><\/tr><tr><td><\/td><td><\/td><td>9 mg<\/td><td>45.4 lbs (19.1%)<\/td><td>Up to 1.6%<\/td><\/tr><tr><td><\/td><td><\/td><td>12 mg<\/td><td>49.6 lbs (20.8%)<\/td><td>Up to 1.6%<\/td><\/tr><tr><td><strong>TRIUMPH-3<\/strong><\/td><td>Adults with severe obesity + cardiovascular disease (\u00b1 T2D)<\/td><td>9 mg \/ 12 mg<\/td><td>Up to 55.8 lbs (22.6%) at 80 weeks<\/td><td>Not specified<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Retatrutide:<\/strong> First-in-class <strong>triple hormone receptor agonist<\/strong> simultaneously targeting <strong>GIP<\/strong> (glucose-dependent insulinotropic polypeptide), <strong>GLP-1<\/strong> (glucagon-like peptide-1), and <strong>glucagon<\/strong> receptors<\/li>\n\n\n\n<li><strong>Mechanism Advantage:<\/strong> Triple agonism leverages complementary pathways for enhanced metabolic effects compared to single or dual agonists, potentially delivering superior weight loss and glycemic control<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Investigational compound representing Lilly&#8217;s next-generation approach beyond current GLP-1 mono-agonists (tirzepatide) and competitors&#8217; dual agonists<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Subcutaneous once-weekly injection, consistent with Lilly&#8217;s established delivery platform<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-trial-design-amp-patient-populations\" class=\"wp-block-heading\">Trial Design &amp; Patient Populations<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>TRIUMPH-2:<\/strong> Focused on adults with <strong>obesity and type 2 diabetes<\/strong>, evaluating three dose levels (4 mg, 9 mg, 12 mg) against placebo<\/li>\n\n\n\n<li><strong>TRIUMPH-3:<\/strong> Targeted adults with <strong>severe obesity and established cardiovascular disease<\/strong>, with or without type 2 diabetes, assessing higher dose ranges (9 mg, 12 mg)<\/li>\n\n\n\n<li><strong>Duration:<\/strong> TRIUMPH-3 results reported at <strong>80 weeks<\/strong>, demonstrating sustained efficacy over nearly two years of treatment<\/li>\n\n\n\n<li><strong>Primary Endpoint:<\/strong> Both studies met their primary endpoints with <strong>statistically significant and clinically meaningful weight loss<\/strong> across all dose groups<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-competitive-positioning\" class=\"wp-block-heading\">Market Impact &amp; Competitive Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Obesity Market Expansion:<\/strong> Results reinforce the massive commercial opportunity in obesity pharmacotherapy, with global market projected to exceed <strong>$100 billion by 2030<\/strong><\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> Retatrutide&#8217;s <strong>22.6% average weight loss<\/strong> significantly exceeds results from current GLP-1 therapies (semaglutide: ~15%, tirzepatide: ~20%) and positions Lilly at the forefront of next-generation obesity treatments<\/li>\n\n\n\n<li><strong>Cardiovascular Indication:<\/strong> TRIUMPH-3 specifically addresses patients with <strong>established cardiovascular disease<\/strong>, a high-risk population with significant unmet need and potential for premium pricing<\/li>\n\n\n\n<li><strong>Pipeline Leadership:<\/strong> Demonstrates Lilly&#8217;s ability to innovate beyond tirzepatide (Mounjaro\/Zepbound) and maintain leadership in the incretin-based therapeutic space<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Potential:<\/strong> Analysts project peak annual sales of <strong>$15-20 billion<\/strong> for retatrutide if approved, representing substantial upside beyond Lilly&#8217;s current obesity franchise<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Strong Phase 3 data supports accelerated regulatory submissions in major markets, with potential approval timeline in <strong>2027-2028<\/strong><\/li>\n\n\n\n<li><strong>Manufacturing Scale-Up:<\/strong> Lilly has already invested in significant manufacturing capacity expansion to support anticipated demand for next-generation obesity therapies<\/li>\n\n\n\n<li><strong>Pricing Strategy:<\/strong> Premium pricing expected given superior efficacy profile, with potential for value-based reimbursement agreements with payers<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-investment-considerations\" class=\"wp-block-heading\">Investment Considerations<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Leadership:<\/strong> Results solidify Lilly&#8217;s position as the innovation leader in metabolic disease therapeutics, potentially extending its competitive moat for years<\/li>\n\n\n\n<li><strong>Risk Mitigation:<\/strong> Successful development of retatrutide provides pipeline diversification beyond tirzepatide and reduces dependency on single-product success<\/li>\n\n\n\n<li><strong>Global Opportunity:<\/strong> Obesity represents a worldwide epidemic, providing international commercial opportunities beyond U.S. and European markets<\/li>\n\n\n\n<li><strong>Shareholder Value:<\/strong> Continued pipeline success supports Lilly&#8217;s commitment to returning value through dividends and share repurchases while funding innovation<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical trial results, regulatory pathways, and commercial expectations. Actual results may differ due to regulatory decisions, safety findings, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly and Company (NYSE: LLY) announced on July 23, 2026 positive topline results from&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[17,199,4361,911,86],"class_list":["post-70600","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-eli-lilly","tag-hot-targets","tag-nyse-lly","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lilly&#039;s Retatrutide Delivers Up to 22.6% Weight Loss in Phase 3 Trials, Establishing Triple Agonist Leadership in Obesity Market - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly and Company (NYSE: LLY) announced on July 23, 2026 positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating retatrutide, an investigational first-in-class triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. The studies demonstrated substantial weight loss in adults with obesity and its complications, including type 2 diabetes and established cardiovascular disease, positioning retatrutide as a potential best-in-class therapy in the rapidly expanding obesity treatment market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70600\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lilly&#039;s Retatrutide Delivers Up to 22.6% Weight Loss in Phase 3 Trials, Establishing Triple Agonist Leadership in Obesity Market\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly and Company (NYSE: LLY) announced on July 23, 2026 positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating retatrutide, an investigational first-in-class triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. The studies demonstrated substantial weight loss in adults with obesity and its complications, including type 2 diabetes and established cardiovascular disease, positioning retatrutide as a potential best-in-class therapy in the rapidly expanding obesity treatment market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70600\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-24T13:04:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-24T13:04:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70600#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70600\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lilly&#8217;s Retatrutide Delivers Up to 22.6% Weight Loss in Phase 3 Trials, Establishing Triple Agonist Leadership in Obesity Market\",\"datePublished\":\"2026-07-24T13:04:23+00:00\",\"dateModified\":\"2026-07-24T13:04:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70600\"},\"wordCount\":577,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"Eli Lilly\",\"Hot targets\",\"NYSE: LLY\",\"Obesity\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70600#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70600\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70600\",\"name\":\"Lilly's Retatrutide Delivers Up to 22.6% Weight Loss in Phase 3 Trials, Establishing Triple Agonist Leadership in Obesity Market - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-24T13:04:23+00:00\",\"dateModified\":\"2026-07-24T13:04:25+00:00\",\"description\":\"Eli Lilly and Company (NYSE: LLY) announced on July 23, 2026 positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating retatrutide, an investigational first-in-class triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. The studies demonstrated substantial weight loss in adults with obesity and its complications, including type 2 diabetes and established cardiovascular disease, positioning retatrutide as a potential best-in-class therapy in the rapidly expanding obesity treatment market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70600#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70600\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70600#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lilly&#8217;s Retatrutide Delivers Up to 22.6% Weight Loss in Phase 3 Trials, Establishing Triple Agonist Leadership in Obesity Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lilly's Retatrutide Delivers Up to 22.6% Weight Loss in Phase 3 Trials, Establishing Triple Agonist Leadership in Obesity Market - Insight, China&#039;s Pharmaceutical Industry","description":"Eli Lilly and Company (NYSE: LLY) announced on July 23, 2026 positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating retatrutide, an investigational first-in-class triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. The studies demonstrated substantial weight loss in adults with obesity and its complications, including type 2 diabetes and established cardiovascular disease, positioning retatrutide as a potential best-in-class therapy in the rapidly expanding obesity treatment market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70600","og_locale":"en_US","og_type":"article","og_title":"Lilly's Retatrutide Delivers Up to 22.6% Weight Loss in Phase 3 Trials, Establishing Triple Agonist Leadership in Obesity Market","og_description":"Eli Lilly and Company (NYSE: LLY) announced on July 23, 2026 positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating retatrutide, an investigational first-in-class triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. The studies demonstrated substantial weight loss in adults with obesity and its complications, including type 2 diabetes and established cardiovascular disease, positioning retatrutide as a potential best-in-class therapy in the rapidly expanding obesity treatment market.","og_url":"https:\/\/flcube.com\/?p=70600","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-24T13:04:23+00:00","article_modified_time":"2026-07-24T13:04:25+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70600#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70600"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lilly&#8217;s Retatrutide Delivers Up to 22.6% Weight Loss in Phase 3 Trials, Establishing Triple Agonist Leadership in Obesity Market","datePublished":"2026-07-24T13:04:23+00:00","dateModified":"2026-07-24T13:04:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70600"},"wordCount":577,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","Eli Lilly","Hot targets","NYSE: LLY","Obesity"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70600#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70600","url":"https:\/\/flcube.com\/?p=70600","name":"Lilly's Retatrutide Delivers Up to 22.6% Weight Loss in Phase 3 Trials, Establishing Triple Agonist Leadership in Obesity Market - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-24T13:04:23+00:00","dateModified":"2026-07-24T13:04:25+00:00","description":"Eli Lilly and Company (NYSE: LLY) announced on July 23, 2026 positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating retatrutide, an investigational first-in-class triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. The studies demonstrated substantial weight loss in adults with obesity and its complications, including type 2 diabetes and established cardiovascular disease, positioning retatrutide as a potential best-in-class therapy in the rapidly expanding obesity treatment market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70600#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70600"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70600#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lilly&#8217;s Retatrutide Delivers Up to 22.6% Weight Loss in Phase 3 Trials, Establishing Triple Agonist Leadership in Obesity Market"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70600","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70600"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70600\/revisions"}],"predecessor-version":[{"id":70602,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70600\/revisions\/70602"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70600"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70600"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70600"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}